SOT 2025

InSphero at the SOT 2025

Join us at the SOT 2025 in Orlando, Florida. This premier event for toxicology professionals is the perfect opportunity to explore the latest advancements in the field. Visit our booth #1211 to discover how our innovative solutions transform toxicological research and drive safety and sustainability progress.

Don’t miss out on all the exciting activities we’ve planned during SOT 2025, happening from Sunday, March 16, to Thursday, March 20. We can’t wait to connect with you there!

Meet our Team at the SOT 2025

Jan Lichtenberg

Jan Lichtenberg, PhD

CEO and Co-Founder
Madhu Nag

Madhu Nag, PhD

Chief Scientific Officer
Bruno Filippi

Bruno Filippi, PhD

Vice President, Liver Safety

Arumugham (Ragoo) Raghunathan, PhD

Senior Director Business Development

Arnab China, PhD

Business Development Manager

Our Booth at the SOT 2025

Visit our booth #1211 and discover our 3D InSight™ Liver Safety - Practical, Physiological & Cost-effective 3D In Vitro Solutions for DILI Assessment

Poster at the SOT 2025

Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs

Date: Monday, 17 March, 2025 | 9:15 - 11:45 AM

Poster number: 3264

Bruno Filippi

Bruno Filippi, PhD

Vice President, Liver Safety

Exhibitor-Hosted Session at the SOT 2025

The 3D InSight™ Liver Microtissues Platform: a Versatile Tool for In Vitro Hepatotoxicity Studies

Date: Wednesday, 19 March, 2025 | 12:15 - 1:15 PM

Location: W208A

The 3D InSight™ Liver Microtissue technology enables the large-scale production of miniaturized and standardized liver spheroids made of primary hepatocytes and non-parenchymal liver cells. The 3D InSight™ Liver Microtissue is a versatile micro-physiological liver system to perform hepatotoxicity studies during the entire drug discovery and development process, from initial screenings of large compound sets to detailed investigations aiming at uncovering mechanisms of toxicity. The utility of liver microtissues in the drug development process will also be exemplified by Piyush Bajaj, distinguished scientist working in the investigative toxicology department at Sanofi, in a presentation on how liver microtissues played a key role in the derisking of Amcenestrant, an investigational oral selective estrogen receptor degrader currently being evaluated for the treatment of breast cancer.

Bruno Filippi

Bruno Filippi, PhD

Vice President, Liver Safety
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

Webinar registrarion

Fill in the form below to register

View resource

Fill in the form below to view this resource